The Rules Have Changed: Decentralized Clincal Trials for Drugs

In this episode, Partner and Co-Chair of the Firm’s Health Care Practice Group, and Partner Monica Chmielweski are joined by Jodi Akin, Founder and CEO of Hawthorne Effect. Hawthorne Effect has embraced the decentralized clinical trial model and is dedicated to enriching the quality, experience, diversity, and access to clinical trials for patients, providers, and sponsors. With Jodi, we explore the newly released FDA Guidance, Decentralized Clinical Trials for Drugs, Biological Products, and Devices, and how Hawthorne Effect was positioned for this guidance and what steps it will take to adapt its practices. We also explore the unique opportunities afforded by conducting decentralized clinical trials